Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer

NCT00674206

Breast Cancer

TERMINATED PHASE2

Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors

NCT07046650

Advanced Solid Tumors

RECRUITING PHASE2

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

NCT00003723

Malignant Mesothelioma

COMPLETED PHASE2

Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors

NCT00004090

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

NCT02256982

Unresectable Intrahepatic Cholangiocarcinoma Resectable Intrahepatic Cholangiocarcinoma

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Melanoma Nausea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Metastatic melanoma treatment with Dartmouth regimen

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed diagnosis metastatic melanoma
* 18 years and older
* undergoing chemotherapy with Dartmouth regimen
* medically stable to receive chemotherapy per physical and clinical laboratory tests

Exclusion Criteria

* No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy
* No cognitive disorder that impairs symptom assessment
* No other investigational agent
* Inability to swallow medications for nausea and vomiting
* No gastric outlet obstruction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No